

**PROVIDER NOTIFICATION OF RETAIL DRUG
POLICY CRITERIA CHANGE**

| Drug Impacted | CRITERIA CHANGE | EFFECTIVE DATE | Formulary |
|----------------------|---|-----------------------|-----------------------------------|
| Poteligeo | Added coverage for Adult T-cell Leukemia/Lymphoma when used in combination with CHOP per NCCN | 6/14/2026 | Essential |
| Zolinza | Added coverage for relapsed/refractory Hodgkin lymphoma, per NCCN. | 6/14/2026 | Standard, Metallic, and Essential |
| Imfinzi | For gastric, gastroesophageal junction, and esophageal adenocarcinoma, added coverage for clinical node negative tumor in combination with FLOT per NCCN. Added coverage for colorectal adenocarcinoma and small bowel adenocarcinoma per NCCN. | 6/14/2026 | Essential |
| Idhifa | Added coverage for subsequent treatment of myelodysplastic syndromes (MDS), per NCCN. | 6/14/2026 | Standard, Exchange, Essential |
| Vanflyta | Added coverage for myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia in chronic or blast phase, per NCCN. | 6/14/2026 | Standard and Essential |
| Ojjaara | Added coverage for myeloid/lymphoid neoplasms with eosinophilia, per NCCN. | 6/14/2026 | Essential |
| Vonjo | Added coverage for myeloid/lymphoid neoplasms with eosinophilia, per NCCN. | 6/14/2026 | Essential |
| azacitidine-Vidaza | For blastic plasmacytoid dendritic cell neoplasm (BPDCN), removed criteria for clinical setting per NCCN. | 6/14/2026 | Metallic and Essential |
| decitabine | For blastic plasmacytoid dendritic cell neoplasm (BPDCN), removed criteria for clinical setting per NCCN. | 6/14/2026 | Metallic and Essential |
| Jakafi | Added coverage for immune effector cell-parkinsonism related to B-cell associated maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, per NCCN. Added Jakafi XR to criteria, per FDA label update. | 6/14/2026 | Standard, Metallic and Essential |
| Besremi | Added coverage for chronic myeloid leukemia, essential thrombocythemia, myelofibrosis, systemic mastocytosis, mycosis fungoides/Sézary syndrome, primary cutaneous CD30+ T-cell lymphoproliferative disorders, and adult T-cell leukemia/lymphoma per NCCN. | 6/14/2026 | Standard and Essential |
| Onureg | For peripheral T-cell lymphomas added coverage for progressive disease per NCCN. | 6/14/2026 | Standard and Essential |
| Sylvant | Added coverage for lymphocyte-engager related toxicities when used in combination with tocilizumab per NCCN. Added coverage for Kaposi-sarcoma | 6/14/2026 | Essential |

| | | | |
|--|---|-----------|-----------------------------------|
| | associated herpesvirus (KSHV) - Associated Inflammatory Cytokine syndrome (KICS) per NCCN. | | |
| temozolomide-Temodar | Added coverage for neuroblastoma when used in combination with irinotecan, naxitamab-gqgk, and sargramostim per NCCN | 6/14/2026 | Standard, Metallic and Essential |
| Rytelo | Added coverage for member who has not responded to or has lost response to luspatercept-aamt (Reblozyl) per NCCN. | 6/14/2026 | Essential |
| Arcalyst | Updated tuberculosis (TB) testing requirement to "Member has been evaluated for TB infection prior to initiation of treatment with a biologic or targeted synthetic drug associated with an increased risk of TB." | 6/14/2026 | Standard, Essential, and Metallic |
| Crenessity | Updated 1 month stable glucocorticoid requirement to currently receiving glucocorticoids and will continue glucocorticoids in combination with requested drug per FDA label. | 6/14/2026 | Standard and Essential |
| Fensolvi | For central precocious puberty: 1) Specified pubertal response to gonadotropin releasing hormone (GnRH) agonist test or pubertal level of luteinizing hormone (LH) on a third-generation LH assay as based on laboratory reference range. 2) Clarified pubertal level of LH as "pubertal basal level". 3) For continuation of therapy, removed requirement that member is currently receiving the requested medication through a paid pharmacy or medical benefit. | 6/14/2026 | Essential |
| Genotropin, Humatrope, Norditropin, Saizen, Zomacton, Nutropin AQ, Omnitrope | 1) Expanded growth chart documentation to include chart notes or medical record documentation showing heights and growth velocities. 2) Small for gestational age: Removed birth weight or length less than 3rd percentile option per updated International Consensus Guideline on Small for Gestational Age definition. | 6/14/2026 | Standard, Metallic and Essential |
| Ilaris | 1) For Adult-Onset Still's disease, removed nonsteroidal anti-inflammatory drugs (NSAIDs)/corticosteroid/conventional synthetic drug step per EULAR/Paediatric Rheumatology European Society (PReS) Still's disease guideline. 2) Updated tuberculosis (TB) testing requirement to "Member has been evaluated for TB infection prior to initiation of treatment with a biologic or targeted | 6/14/2026 | Standard Essential |

| | | | |
|------------------|---|-----------|-----------------------------------|
| | synthetic drug associated with an increased risk of TB." | | |
| Kalydeco | Updated prescriber specialties to include prescribers specialized in the treatment of cystic fibrosis. | 6/14/2026 | Standard Metallic Essential |
| Leuprolide | For central precocious puberty: 1) Specified pubertal response to gonadotropin releasing hormone (GnRH) agonist test or pubertal level of luteinizing hormone (LH) on a third-generation LH assay as based on laboratory reference range. 2) Clarified pubertal level of LH as "pubertal basal level". 3) For continuation of therapy, removed requirement that member is currently receiving the requested medication through a paid pharmacy or medical benefit. | 6/14/2026 | Standard Metallic Essential |
| Lupron Depot-PED | For central precocious puberty: 1) Specified pubertal response to gonadotropin releasing hormone (GnRH) agonist test or pubertal level of luteinizing hormone (LH) on a third-generation LH assay as based on laboratory reference range. 2) Clarified pubertal level of LH as "pubertal basal level". 3) For continuation of therapy, removed requirement that member is currently receiving the requested medication through a paid pharmacy or medical benefit. | 6/14/202 | Standard Metallic Essential |
| Ngenla | Expanded growth chart documentation to include chart notes or medical record documentation showing heights and growth velocities. | 6/14/2026 | Essential |
| Orkambi | Updated prescriber specialties requirement to include prescribers specialized in the treatment of cystic fibrosis. | 6/14/2026 | Standard Metallic Essential |
| Skytrofa | Expanded growth chart documentation to include chart notes or medical record documentation showing heights and growth velocities. | 6/14/2026 | Essential |
| Supprelin LA | For central precocious puberty: 1) Specified pubertal response to gonadotropin releasing hormone (GnRH) agonist test or pubertal level of luteinizing hormone (LH) on a third-generation LH assay as based on laboratory reference range. 2) Clarified pubertal level of LH as "pubertal basal level". | 6/14/2026 | Essential and Metallic |

| | | | |
|--|---|------------|-----------------------------------|
| | 3) For continuation of therapy, removed requirement that member is currently receiving the requested medication through a paid pharmacy or medical benefit. | | |
| Symdeko | Updated prescriber specialties to include prescribers specialized in the treatment of cystic fibrosis. | 06/14/2026 | Standard Metallic Essential |
| Synarel | For central precocious puberty: 1) Specified pubertal response to gonadotropin releasing hormone (GnRH) agonist test or pubertal level of luteinizing hormone (LH) on a third-generation LH assay as based on laboratory reference range. 2) Clarified pubertal level of LH as "pubertal basal level". 3) For continuation of therapy, removed requirement that member is currently receiving the requested medication through a paid pharmacy or medical benefit. | 6/14/2026 | Metallic |
| Triptodur | For central precocious puberty: 1) Specified pubertal response to gonadotropin releasing hormone (GnRH) agonist test or pubertal level of luteinizing hormone (LH) on a third-generation LH assay as based on laboratory reference range. 2) Clarified pubertal level of LH as "pubertal basal level". 3) For continuation of therapy, removed requirement that member is currently receiving the requested medication through a paid pharmacy or medical benefit. | 6/14/2026 | Essential and Metallic |
| Voxzogo | Expanded growth chart documentation to include chart notes or medical record documentation showing heights and growth velocities. | 6/14/2026 | Essential |
| Actemra,Avtozma,T ofidence,Tyenne,to cilizumab-aazg,tocilizumab-anoh | 1) Added coverage for Kaposi-sarcoma herpesvirus (KSHV)-Associated Inflammatory Cytokine Syndrome (KICS) per NCCN. 2) For multicentric Castleman disease, added option for active disease with no organ failure that is human immunodeficiency virus (HIV)-negative and human herpesvirus-8-negative or fulminant/severe disease that is human herpesvirus-8-negative per NCCN. 3) For giant cell arteritis continuation criteria, added acute phase reactants to list of improvements in signs and systems of the condition. | 07/01/2026 | Metallic and Essential |

| | | | |
|---|---|-----------|-----------------------------------|
| | 4) Updated tuberculosis (TB) testing requirement to "Member has been evaluated for TB infection prior to initiation of treatment with a biologic or targeted synthetic drug associated with an increased risk of TB." | | |
| Bimzelx | 1) For hidradenitis suppurativa (HS) initial criteria, updated the duration for previous oral antibiotic use to at least 8 weeks (previously at least 90 days) per North American clinical management guidelines for HS. 2) Updated tuberculosis (TB) testing requirement to "Member has been evaluated for TB infection prior to initiation of treatment with a biologic or targeted synthetic drug associated with an increased risk of TB." | 7/01/2026 | Essential |
| Cosentyx | 1) For hidradenitis suppurativa initial criteria, updated oral antibiotic trial to at least 8 weeks (previously at least 90 days) per North American clinical management guidelines for HS. 2) Updated tuberculosis (TB) testing requirement to "Member has been evaluated for TB infection prior to initiation of treatment with a biologic or targeted synthetic drug associated with an increased risk of TB." | 7/1/2026 | Standard Exchange Essential |
| Enbrel | For hidradenitis suppurativa initial criteria, updated oral antibiotic trial to at least 8 weeks (previously at least 90 days) per North American clinical management guidelines for HS. | 7/1/2026 | Standard Exchange Essential |
| Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Humira, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry, adalimumab-aacf, adalimumab-aaty, adalimumab-adaz, adalimumab-adbm, adalimumab-bwwd, adalimumab-fkjp, adalimumab-ryvk | For hidradenitis suppurativa initial criteria, updated oral antibiotic trial to at least 8 weeks (previously at least 90 days) per North American clinical management guidelines for HS. | 7/1/2026 | Standard Exchange Essential |
| Illumya | Updated tuberculosis (TB) testing requirement to "Member has been evaluated for TB infection prior to initiation of treatment with a biologic or targeted synthetic drug associated with an increased risk of TB." | 7/1/2026 | Essential |

| | | | |
|--|--|-----------|-----------------------------------|
| Kevzara | For giant cell arteritis continuation criteria, added acute phase reactants to list of improvements in signs and systems of the condition. | 7/1/2026 | Standard Exchange Essential |
| Kineret | 1) For Adult-Onset Still's disease, removed nonsteroidal anti-inflammatory drugs NSAID/corticosteroid/conventional synthetic drug step per EULAR/Paediatric Rheumatology European Society (PReS) Still's disease guideline. 2) Updated tuberculosis (TB) testing requirement to "Member has been evaluated for TB infection prior to initiation of treatment with a biologic or targeted synthetic drug associated with an increased risk of TB." | 7/1/2026 | Essential |
| Rinvoq | For giant cell arteritis continuation criteria, added acute phase reactants to list of improvements in signs and systems of the condition. | 7/1/2026 | Essential |
| Siliq | Updated tuberculosis (TB) testing requirement to "Member has been evaluated for TB infection prior to initiation of treatment with a biologic or targeted synthetic drug associated with an increased risk of TB." | 7/1/2026 | Essential |
| Sotyktu | Updated tuberculosis (TB) testing requirement to "Member has been evaluated for TB infection prior to initiation of treatment with a biologic or targeted synthetic drug associated with an increased risk of TB." | 7/1/2026 | Standard and Essential |
| Taltz | Updated tuberculosis (TB) testing requirement to "Member has been evaluated for TB infection prior to initiation of treatment with a biologic or targeted synthetic drug associated with an increased risk of TB." | 7/1/2026 | Metallic and Essential |
| Avsola, Inflectra, Remicade, Renflexis, Zymfentra, infliximab, infliximab-abda | For hidradenitis suppurativa initial criteria, updated oral antibiotic trial to at least 8 weeks (previously at least 90 days) per North American clinical management guidelines for HS. | 7/1/2026 | Metallic and Essential |
| lapatinib-Tykerb | For breast cancer, updated to recurrent unresectable disease; removed coverage for advanced disease or disease with no response to preoperative systemic therapy for HR+/HER2+ disease; and added place in therapy as fourth line and beyond when used in combination with trastuzumab or capecitabine per NCCN. For colorectal cancer, added requirement for primary therapy when intensive therapy not recommended and added requirement for no previous HER2 inhibitor use when used for | 7/29/2026 | Standard, Metallic, and Essential |

| | | | |
|----------------|---|-----------|-----------------------------------|
| | subsequent therapy per NCCN. Added coverage for use as initial therapy for unresectable metachronous metastases per NCCN. | | |
| Tecentriq | For non-small cell lung cancer, added additional contraindicated mutations, aligned use for subsequent treatment as a single agent, and specified use for adjuvant treatment for stage IB to IIIB disease, per NCCN. For hepatocellular carcinoma, expanded coverage for progressive, unresectable, or metastatic disease, per NCCN. For melanoma, specified use as subsequent treatment when used in combination with cobimetinib and vemurafenib, per NCCN. Added coverage for small bowel adenocarcinoma, per NCCN. | 7/29/2026 | Essential |
| Kisqali Femara | Updated verbiage from recurrent to recurrent unresectable breast cancer to align with NCCN. Removed early stage requirement for adjuvant treatment of breast cancer to align with NCCN. Added coverage for adjuvant treatment of endometrial carcinoma, per NCCN. | 7/29/2026 | Standard and Essential |
| Kisqali | Updated verbiage from recurrent to recurrent unresectable breast cancer to align with NCCN. Removed early stage requirement for adjuvant treatment of breast cancer to align with NCCN. Added coverage for adjuvant treatment of endometrial carcinoma, per NCCN. | 7/29/2026 | Standard, Metallic, and Essential |
| Verzenio | Updated verbiage from recurrent to recurrent unresectable breast cancer to align with NCCN. Removed early stage requirement for adjuvant treatment of breast cancer to align with NCCN. Added coverage for treatment of recurrent or metastatic endometrial carcinoma in combination with fulvestrant, per NCCN. Added coverage for adjuvant treatment of endometrial carcinoma, per NCCN. Added coverage for liposarcoma, per NCCN. | 7/29/2026 | Standard, Metallic, and Essential |
| Ibrance | Updated verbiage from recurrent to recurrent unresectable breast cancer to align with NCCN. Removed retroperitoneal requirement from unresectable liposarcoma to align with NCCN. Added coverage for retroperitoneal well-differentiated or dedifferentiated locally advanced or metastatic liposarcoma per Lexicomp. | 7/29/2026 | Standard and Essential |

| | | | |
|------------------|---|-----------|----------------------------------|
| | Added coverage for endometrial carcinoma and uterine sarcoma per NCCN. | | |
| eribulin-Halaven | For breast cancer, updated to recurrent unresectable disease and added place in therapy as fourth line and beyond when used with margetuximab and trastuzumab per NCCN Added coverage for dedifferentiated liposarcoma with or without concurrent well-differentiated liposarcoma and epithelioid hemangioendothelioma per NCCN | 7/29/2026 | Essential |
| Truqap | For breast cancer, updated from recurrent to recurrent unresectable disease and removed specification that disease recurrence was within 12 months of adjuvant therapy per NCCN. | 7/29/2026 | Essential, Standard and Metallic |
| Opdivo | Removed coverage for subsequent treatment of stage II, recurrent and persistent urothelial carcinoma bladder cancer due to lack of compendial support. For Merkel cell carcinoma added coverage for regional and in transit disease when used in combination with ipilimumab and regional disease when used as a single agent, per NCCN. Endometrial carcinoma updated from recurrent to recurrent unresectable and added coverage for metastatic disease, per NCCN. Added coverage for uterine sarcoma, per NCCN. Added requirement for PD-L1 \geq 1 gastric cancer that disease is HER 2 negative, per NCCN. Added coverage for vulvar cancer, cervical cancer, vaginal cancer and adrenal gland tumors in combination with ipilimumab, per NCCN. Added requirement for Kaposi sarcoma that disease is advanced, per NCCN. | 7/29/2026 | Essential |
| Perjeta | Added FDA approved biosimilar, Poherty. For breast cancer, added requirement for clinical stage for adjuvant treatment per Label and NCCN. Updated verbiage from recurrent to recurrent unresectable disease to align with NCCN. Added coverage in combination with Enhertu or aromatase inhibitor, Ibrance and trastuzumab per NCCN. Added documentation requirement for HR status For colorectal cancer, added coverage for initial treatment of unresectable metachronous metastases per NCCN. For appendiceal neoplasms and cancers, added coverage for goblet cell adenocarcinoma and undifferentiated carcinoma not otherwise specified per NCCN. Added requirement that member has not | 7/29/2026 | Essential |

| | | | |
|----------------------|--|-----------|------------------------|
| | received previous treatment with HER2 inhibitor per NCCN. Added coverage for small bowel adenocarcinoma per NCCN. | | |
| Inluriyo | Updated verbiage from ER positive to HR positive to align with NCCN Added coverage for recurrent unresectable disease per NCCN Updated verbiage for non-postmenopausal member to if the member is not postmenopausal, hormone suppression is being achieved through surgery, irradiation, or concomitant use with a gonadotrophin-releasing hormone agonist (GnRH) (e.g., leuprolide [Lupron]) to align with NCCN. Added criteria for regimens per NCCN. | 7/29/2026 | Essential |
| Tibsovo | For the treatment of chondrosarcoma, specified use as a single agent, per NCCN. For the treatment of central nervous system cancers, specified that Tibsovo may be used in members who are unable to tolerate vorasidenib, per NCCN. Added coverage for recurrent or progressive high grade gliomas, per NCCN. | 7/29/2026 | Standard and Essential |
| Opdivo Qvantig | Added coverage for appendiceal neoplasms and cancers, anal carcinoma, Merkel cell carcinoma, CNS brain metastases, gestational trophoblastic neoplasia, pleural or peritoneal mesothelioma, endometrial carcinoma, vulvar cancer, small cell lung cancer, cervical cancer, Kaposi sarcoma, bone cancer, soft tissue sarcoma, anaplastic thyroid carcinoma, histologic (Richter) transformation to diffuse large B-cell lymphoma, vaginal cancer, squamous cell skin carcinoma, ampullary adenocarcinoma, small bowel adenocarcinoma, per NCCN. Updated continuation of therapy language for renal cell carcinoma to a maximum of 24 months of treatment when used in combination with cabozantinib, per NCCN. | 7/29/2026 | Essential |
| Bizengri | For non-small cell lung cancer and pancreatic adenocarcinoma, added coverage for recurrent disease and requirement for single agent therapy per NCCN. Added coverage for biliary tract cancers per NCCN. | 7/29/2026 | Essential |
| fulvestrant-Faslodex | Added documentation requirement for HER2 activating mutation status | 7/29/2026 | Metallic and Essential |

| | | | |
|-----------|--|-----------|-----------------------------------|
| | <p>For breast cancer, updated to recurrent unresectable disease and added coverage for triple negative metastatic disease with HER2 activating mutation per NCCN</p> <p>For endometrial carcinoma, added coverage for use in combination with abemaciclib for ER positive disease per NCCN</p> <p>Added requirement for staging for endometrial stromal sarcoma per NCCN</p> | | |
| Venclexta | <p>Added coverage for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) use in combination with zanubrutinib (Brukinsa), per NCCN.</p> <p>Removed coverage of use in combination with low-dose cytarabine for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) to align with NCCN.</p> <p>Added coverage for refractory multiple myeloma, per Lexicomp.</p> <p>Added coverage for multiple myeloma with CNS disease, per NCCN.</p> <p>Added coverage for systemic light chain amyloidosis in combination with daratumumab (Darzalex) or daratumumab and hyaluronidase-fihj (Darzalex Faspro), per NCCN.</p> <p>Updated coverage for B-Cell Acute Lymphoblastic Leukemia (B-ALL) to allow frontline use, per NCCN.</p> <p>Added coverage for POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes) Syndrome, Monoclonal Immunoglobulin Deposition Disease (MIDD), Monoclonal Gammopathy of Renal Significance (MGRS), and Histologic (Richter) transformation to diffuse large B-cell lymphoma, per NCCN.</p> | 7/29/2026 | Standard, Metallic, and Essential |
| Yervoy | <p>Updated appendiceal adenocarcinoma to appendiceal neoplasms and appendiceal cancers to align with NCCN.</p> <p>Added coverage for dedifferentiated liposarcoma and epithelioid hemangioendothelioma, per NCCN.</p> <p>Added coverage for in-transit disease for Merkel cell carcinoma, per NCCN.</p> <p>Added coverage for cervical cancer, adrenal gland tumors, uterine neoplasms, vaginal cancer and vulvar cancer, per NCCN.</p> | 7/29/2026 | Essential |

| | | | |
|----------------------|---|-----------|-----------------------------------|
| | Updated continuation of therapy for peritoneal mesothelioma to a maximum of 24 months of treatment, per NCCN. | | |
| Komzifti | Removed requirement that no other satisfactory alternative treatment options are available to align with NCCN. Added requirement that medication will be used as a single agent per NCCN. | 7/29/2026 | Essential |
| Nerlynx | For breast cancer, per NCCN: removed staging requirement for adjuvant treatment; updated to recurrent unresectable disease; added place of therapy as 4th line and beyond when used in combination with capecitabine; added coverage for brain metastases in combination with ado-trastuzumab per NCCN | 7/29/2026 | Standard and Essential |
| bexarotene-Targretin | Removed coverage for Adult T-cell leukemia/lymphoma under the gel formulation per NCCN. | 7/29/2026 | Standard, Metallic, and Essential |
| Valchlor | Removed coverage for Adult T-Cell Leukemia/Lymphoma, per NCCN. | 7/29/2026 | Standard and Essential |
| Datroway | For the treatment of HR-positive breast cancer, specified use as a single agent and that the member is not an candidate for treatment with fam-trastuzumab deruxtecan-nxki (Enhertu), per NCCN. Added coverage for triple negative breast cancer, per NCCN. For the treatment of NSCLC, added coverage for recurrent disease and removed the requirement that the member must have received prior treatment with EGFR directed therapy and platinum based chemotherapy, per NCCN. | 7/29/2026 | Essential |
| Talzenna | Updated verbiage from recurrent to recurrent unresectable breast cancer, per NCCN. Removed requirement that prostate cancer has not be treated in metastatic setting, per NCCN. Updated verbiage for prostate cancer from has not progressed on prior novel hormone therapy to member has not received androgen receptor pathway inhibitor (ARPI) therapy, per NCCN. | 7/29/2026 | Essential |
| Lynparza | Removed use in combination with Yonsa (fine-particle abiraterone) for prostate cancer due to lack of compendial support. Updated verbiage for prostate cancer from has not progressed on prior novel hormone therapy to member has not received androgen receptor pathway inhibitor (ARPI) therapy, per NCCN. | 7/29/202 | Standard, Metallic, and Essential |

| | | | |
|------------|---|-----------|------------------------|
| Trodelvy | For triple negative breast cancer, removed requirement that member has received at least one prior regimen when used as a single agent per NCCN, and added coverage for use as first-line therapy in combination with Keytruda for PD-L1 positive disease per NCCN. Added documentation requirement for PD-L1 status. For urothelial carcinoma – bladder cancer, added coverage for Stage 3 disease per NCCN | 7/29/2026 | Essential |
| Phesgo | Added requirement for clinical stage for adjuvant treatment per Label and NCCN. Updated verbiage from recurrent to recurrent unresectable disease to align with NCCN. | 7/29/2026 | Standard and Essential |
| Cyramza | For NSCLC, added requirement for use as first-line therapy in combination with erlotinib per Label and NCCN. For thymic carcinoma, added requirement that medication be used as first-line therapy for recurrent, advanced, or metastatic disease per NCCN. | 7/29/2026 | Essential |
| Daurismo | Added documentation section requiring submission of IDH1 mutational status. For the treatment of acute myeloid leukemia, specified that the medication should be used for low-intensity induction treatment, per NCCN. | 7/29/2026 | Essential |
| Xospata | Limited total duration of maintenance therapy for AML to a total of 26 months, per NCCN. | 7/29/2026 | Standard and Essential |
| Itovebi | Updated verbiage from recurrent to recurrent unresectable breast cancer to align with NCCN. | 7/29/2026 | Metallic and Essential |
| Orserdu | For breast cancer, updated to recurrent unresectable disease per NCCN. | 7/29/2026 | Essential |
| Piqray | For breast cancer, updated to recurrent unresectable disease per NCCN. | 7/29/2026 | Standard and Essential |
| Imjudo | For esophageal, esophagogastric junction, and gastric cancer, updated coverage to require adenocarcinoma per NCCN. | 7/29/2026 | Essential |
| Ixempra | For breast cancer, updated to recurrent unresectable disease and added place in therapy as fourth line and beyond when used in combination with trastuzumab per NCCN | 7/29/2026 | Essential |
| Aldurazyme | Added initial coverage criteria and documentation requirement that member is showing clinical signs and symptoms of disease at baseline. | 7/29/2026 | Essential |

| | | | |
|----------------------|--|-----------|-----------------------------------|
| Elaprase | Added initial coverage criteria and documentation requirement that member is showing clinical signs and symptoms of disease at baseline. | 7/29/2026 | Essential |
| Mepsevii | Added initial coverage criteria and documentation requirement that member is showing clinical signs and symptoms of disease at baseline. | 7/29/2026 | Essential |
| Naglazyme | Added initial coverage criteria and documentation requirement that member is showing clinical signs and symptoms of disease at baseline. | 7/29/2026 | Essential |
| Vimizim | Added initial coverage criteria and documentation requirement that member is showing clinical signs and symptoms of disease at baseline. | 7/29/2026 | Essential |
| Cystagon | Added initial coverage criteria and documentation requirement that member is showing clinical signs and symptoms of disease at baseline. | 7/29/2026 | Standard, Metallic, and Essential |
| Procysbi | Added initial coverage criteria and documentation requirement that member is showing clinical signs and symptoms of disease at baseline. | 7/29/2026 | Standard and Essential |
| sapropterin products | For PKU, added requirement that diagnosis was confirmed by enzyme assay or genetic testing and added requirement that medication will be used in conjunction with a phenylalanine (Phe)-restricted diet to align with FDA label. | 7/29/2026 | Standard, Metallic, and Essential |
| Vyjuvek | Added requirements that member has not received a skin graft within the past 3 months to align with trial inclusion criteria and Zevaskyn or Filsuvez will not be used on wounds previously treated with Vyjuvek. | 7/29/2026 | Essential |
| Visudyne | Added criteria that medication must be prescribed by or in consultation with an ophthalmologist. | 7/29/2026 | Essential |
| Xipere | Added the medication must be prescribed by or in consultation with an ophthalmologist. | 7/29/2026 | Essential |
| miglustat products | For Gaucher Disease type 1, added initial coverage criteria and documentation requirement that member is showing clinical signs and symptoms of disease at baseline. For Gaucher Disease type 1, added continuation criteria and documentation requirement that member is receiving benefit from therapy. For Late-onset Pompe disease, specified that member demonstrates a deficiency of enzyme activity 'less than 40% of normal controls' per ACMG Practice Guideline. For late-onset Pompe disease, added initial coverage criteria and documentation requirement that member is showing clinical signs and symptoms of disease at baseline. For Niemann- | 7/29/2026 | Standard and Essential |

| | | | |
|---------------------|--|-----------|-----------------------------------|
| | Pick disease, added continuation criteria that member is receiving benefit from therapy. | | |
| Pombiliti | Specified that member demonstrates a deficiency of enzyme activity 'less than 40% of normal controls' in coverage criteria and documentation per ACMG Practice Guideline. Added initial coverage criteria and documentation requirement that member is showing clinical signs and symptoms of disease at baseline. | 7/29/2026 | Essential |
| betaine-Cystadane | Added initial coverage criteria and documentation requirement that member exhibits clinical signs and symptoms of disease at baseline. For homocystinuria, added documentation requirement showing homocysteine level that is undetectable or present in small amounts, or a substantial decrease in homocysteine level since initiating treatment. For methylmalonic acidemia with homocystinuria, added documentation requirement showing benefit from therapy as evidenced by disease stability or improvement. | 7/29/2026 | Standard, Essential and Metallic |
| Cystaran-Cystadrops | Added initial documentation requirement for presence of corneal cystine crystal accumulation at baseline. Added continuation documentation requirement for corneal cystine crystal accumulation has not increased since initiating therapy. | 7/29/2026 | Standard, Metallic, and Essential |
| Cerezyme | Added initial coverage criteria and documentation requirement that member is showing clinical signs and symptoms of disease at baseline. Added continuation criteria and documentation requirement that member is receiving benefit from therapy. | 7/29/2026 | Essential |
| VPRIV | Added initial coverage criteria and documentation requirement that member is showing clinical signs and symptoms of disease at baseline. Added continuation criteria and documentation requirement that member is receiving benefit from therapy. | 7/29/2026 | Essential |
| Elelyso | Added initial coverage criteria and documentation requirement that member is showing clinical signs and symptoms of disease at baseline. Added continuation criteria and documentation requirement that member is receiving benefit from therapy. | 7/29/2026 | Essential |
| Cerdelga | Added initial coverage criteria and documentation requirement that member is showing clinical signs and symptoms of disease at baseline. Added continuation criteria and documentation requirement that member is receiving benefit from therapy. | 7/29/2026 | Standard, Metallic and Essential |

| | | | |
|----------|--|-----------|------------------------|
| Alyftrek | <p>1) Per FDA label update: Added clinical diagnosis of cystic fibrosis. Removed cystic fibrosis transmembrane conductance regulator (CFTR) gene list. Added requirement for detection of a mutation in the CFTR gene that results in the production of CFTR protein.</p> <p>2) Updated prescriber specialties to include prescribers specialized in the treatment of cystic fibrosis.</p> | 7/29/2026 | Standard and Essential |
| Arikayce | <p>1) Added documentation requirements.</p> <p>2) Added prescriber specialties.</p> <p>3) Added adult age requirement per FDA label.</p> <p>4) Added examples of medications utilized in combination antibacterial regimens for clarity [per American Thoracic Society (ATS), European Respiratory Society (ERS), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and Infectious Diseases Society of America (IDSA) (ATS/ERS/ESCMID/IDSA) clinical practice guideline.</p> | 7/29/2026 | Standard and Essential |
| Benlysta | <p>1) Added prescriber specialties.</p> <p>2) For systemic lupus erythematosus (SLE), added age requirement for members 5 years of age or older per FDA label.</p> <p>3) For lupus nephritis (LN): Updated initial criteria to require kidney biopsy to confirm LN per 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis. If biopsy is contraindicated, the member must be positive for SLE autoantibodies. Added hydroxychloroquine as another example of a standard therapy regimen. Added age requirement for members 5 years of age or older per FDA label.</p> | 7/29/2026 | Standard and Essential |
| Filsuvez | <p>Added criteria that member will not use concomitantly with other topical treatments for the same indication (e.g., Vyjuvek, Zevaskyn).</p> | 7/29/2026 | Essential |
| Gazyva | <p>For lupus nephritis (LN): Updated initial criteria to require kidney biopsy to confirm LN per 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis. If biopsy is contraindicated, the member must be positive for SLE autoantibodies. Added hydroxychloroquine as another example of standard therapy regimen. Added age requirement for members 18 years of</p> | 7/29/2026 | Metallic and Essential |

| | | | |
|---------------------|--|-----------|----------------------------------|
| | age or older per FDA label. Added prescriber specialties. | | |
| Increlex | 1) Expanded growth chart documentation to include chart notes or medical record documentation showing heights and growth velocities. 2) Added prescriber specialty. | 7/29/2026 | Standard, Metallic and Essential |
| Lupkynis | 1) Added prescriber specialties. 2) Added age requirement for 18 years of age or older per FDA label. 3) Updated initial criteria to require kidney biopsy to confirm lupus nephritis per 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis. If biopsy is contraindicated, the member must be positive for SLE autoantibodies. | 7/29/2026 | Essential |
| mifepristone-Korlym | 1) Added requirement to confirm diagnosis of Cushing's syndrome/disease per the Pituitary Society guideline on diagnosis and management of Cushing's disease. 2) Added prescriber specialties. 3) Increased initial approval duration from 6 months to 12 months. 4) Added adult age requirement per FDA label. 5) Added pretreatment fasting plasma glucose and 2-hour plasma glucose as additional options for documentation of glucose intolerance. | 7/29/2026 | Essential |
| Otezla-Otezla XR | 1) Added compendial use for moderate to severe immunotherapy-related inflammatory arthritis per NCCN. 2) Added rheumatologist as a prescriber specialty for immune checkpoint inhibitor-related toxicity. 3) For immunotherapy-related psoriasis and psoriasiform diseases, require inadequate response, intolerance or contraindications to high potency topical corticosteroids (previously medium or high) to align with NCCN guidelines. | 7/26/2026 | Standard, Metallic and Essential |
| Pulmozyme | Added prescriber specialties. | 7/29/2026 | Standard and Essential |
| Reblozyl | 1) For prescriber specialties, separated out by indication. 2) Added coverage criteria for myelodysplastic/myeloproliferative neoplasm with SF3B1 variant and thrombocytosis (MDS/MPN-SF3B1-T). | 7/29/2026 | Essential |
| Saphnelo | 1) Added prescriber specialties. 2) Added age requirement for 18 years of age or older per FDA label. | 7/29/2026 | Essential |
| Tavneos | 1) Added prescriber specialties. | 7/29/2026 | Standard and Essential |

| | | | |
|----------------------------------|---|-----------|-----------------------------------|
| | 2) Added age requirement for members 18 years of age or older per FDA label. | | |
| Trikafta | 1) Per FDA label update: Added clinical diagnosis of cystic fibrosis. Removed cystic fibrosis transmembrane conductance regulator (CFTR) gene list. Added requirement for detection of a mutation in the CFTR gene that results in the production of CFTR protein. 2) Updated prescriber specialties to include prescribers specialized in the treatment of cystic fibrosis. | 7/29/2026 | Standard, Metallic, and Essential |
| Vioice | Added prescriber specialties. | 7/29/2026 | Essential |
| Vykat | Added prescriber specialties. | 7/29/2026 | Essential |
| dichlorphenamide-Keveyis-Ormalvi | 1) Added documentation requirements. 2) Added prescriber specialties. 3) Added serum potassium concentration requirements. | 7/29/2026 | Standard and Essential |
| nintedanib-Ofev | 1) For idiopathic pulmonary fibrosis (IPF): Added transbronchial lung cryobiopsy (TBLC) as another option for diagnosing IPF (usual interstitial pneumonia [UIP], probable UIP, indeterminate UIP) per the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Association (ATS/ERS/JRS/ALAT) guidelines. Added requirement for multidisciplinary review by an IPF experienced radiologist and pulmonologist for UIP diagnosis. Multidisciplinary review will also be required for probable UIP and indeterminate UIP (previously only required if lung biopsy was not conducted). 2) For progressive pulmonary fibrosis: Added documentation of progressive disease. 3) Added prescriber specialties. 4) Updated program name to include generic nintedanib. | 7/29/2026 | Standard, Metallic and Essential |
| pirfenidone-Esbriet | 1) For idiopathic pulmonary fibrosis (IPF): Added transbronchial lung cryobiopsy (TBLC) as another option for diagnosing IPF (usual interstitial pneumonia [UIP], probable UIP, indeterminate UIP) per the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Association (ATS/ERS/JRS/ALAT) guidelines. Added requirement for multidisciplinary review by an IPF experienced radiologist and pulmonologist for UIP | 7/29/2026 | Standard, Metallic and Essential |

| | | | |
|--|--|------------------|---|
| | <p>diagnosis. Multidisciplinary review will also be required for probable UIP and indeterminate UIP (previously only required if lung biopsy was not conducted).</p> <p>2) Added prescriber specialties.</p> | | |
| <p>tasimelteon- Hetlioz-Hetlioz LQ</p> | <p>1) For Non-24-Hour Sleep Wake Disorder (Non-24): Added adult members age requirement per FDA label. Added documentation requirement for diagnosis. Increased initial approval duration from 6 months to 12 months.</p> <p>2) For Smith-Magenis Syndrome (SMS): Added age requirement for 3 years of age or older per FDA label. Added genetic testing requirement for diagnosis confirmation. Increased initial approval duration from 6 months to 12 months.</p> | <p>7/29/2026</p> | <p>Standard, Metallic and Essential</p> |